KR20230105972A - 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 - Google Patents

혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 Download PDF

Info

Publication number
KR20230105972A
KR20230105972A KR1020220001647A KR20220001647A KR20230105972A KR 20230105972 A KR20230105972 A KR 20230105972A KR 1020220001647 A KR1020220001647 A KR 1020220001647A KR 20220001647 A KR20220001647 A KR 20220001647A KR 20230105972 A KR20230105972 A KR 20230105972A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020220001647A
Other languages
English (en)
Korean (ko)
Inventor
정으뜸
유수민
김동건
장지훈
이병철
Original Assignee
주식회사 카나프테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 카나프테라퓨틱스 filed Critical 주식회사 카나프테라퓨틱스
Priority to KR1020220001647A priority Critical patent/KR20230105972A/ko
Priority to CN202280087754.8A priority patent/CN118510799A/zh
Priority to JP2024538390A priority patent/JP2025501913A/ja
Priority to PCT/KR2022/021371 priority patent/WO2023132547A1/ko
Priority to EP22919084.8A priority patent/EP4461745A4/en
Priority to US18/726,333 priority patent/US20250074974A1/en
Priority to AU2022430428A priority patent/AU2022430428A1/en
Publication of KR20230105972A publication Critical patent/KR20230105972A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020220001647A 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 Pending KR20230105972A (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020220001647A KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN202280087754.8A CN118510799A (zh) 2022-01-05 2022-12-27 血管生成抑制剂缀合的抗c3b抗体或抗c5抗体及其用途
JP2024538390A JP2025501913A (ja) 2022-01-05 2022-12-27 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用
PCT/KR2022/021371 WO2023132547A1 (ko) 2022-01-05 2022-12-27 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도
EP22919084.8A EP4461745A4 (en) 2022-01-05 2022-12-27 ANTI-C3B ANTIBODY OR ANTI-C5 ANTIBODY CONJUGATED TO AN ANGIOGENESIS INHIBITOR AND USE THEREOF
US18/726,333 US20250074974A1 (en) 2022-01-05 2022-12-27 Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof
AU2022430428A AU2022430428A1 (en) 2022-01-05 2022-12-27 Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020220001647A KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20230105972A true KR20230105972A (ko) 2023-07-12

Family

ID=87073766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020220001647A Pending KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도

Country Status (7)

Country Link
US (1) US20250074974A1 (https=)
EP (1) EP4461745A4 (https=)
JP (1) JP2025501913A (https=)
KR (1) KR20230105972A (https=)
CN (1) CN118510799A (https=)
AU (1) AU2022430428A1 (https=)
WO (1) WO2023132547A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189030A1 (en) * 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4897690B2 (ja) 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PL3167888T3 (pl) * 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
BRPI0812767A2 (pt) * 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CA3056248A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
WO2019112958A1 (en) 2017-12-05 2019-06-13 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4897690B2 (ja) 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mulling, R.F. et al., FASEB J., 14, 835-46, 2000

Also Published As

Publication number Publication date
CN118510799A (zh) 2024-08-16
EP4461745A4 (en) 2025-07-02
US20250074974A1 (en) 2025-03-06
JP2025501913A (ja) 2025-01-24
WO2023132547A1 (ko) 2023-07-13
AU2022430428A1 (en) 2024-07-04
EP4461745A1 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
KR102687212B1 (ko) Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질
AU2018211985B2 (en) Tissue-specific Wnt signal enhancing molecules and uses thereof
KR102648966B1 (ko) Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
KR101963923B1 (ko) 이중특이적 t 세포 활성화 항원 결합 분자
CN107406508B (zh) 人源化的抗trop-2单克隆抗体及其应用
CN109705218B (zh) Asgpr抗体及其用途
AU2017385274B2 (en) Fusion protein including BDNF
CN109206517B (zh) St2抗原结合蛋白
CN110573528B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
TW201106963A (en) Antigen-binding proteins
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20140041908A (ko) Ｆｃ 도메인에 융합된 항­ｖｅｇｆ 단일 가변 도메인
KR20150030706A (ko) 이중 수용체 길항 항원-결합 단백질 및 그것의 사용
CN112638403A (zh) 包括饰胶蛋白聚糖的多功能蛋白质分子及其用途
TW200821330A (en) Antibodies against CCR5 and uses thereof
CN112262158B (zh) 新型血管生成素2，vegf双特异性拮抗剂
KR20190039256A (ko) 항pd-l1 항체
KR20140093942A (ko) 인간 노치1 디코이
CN111295393B (zh) 靶向干细胞因子及半乳糖凝集素-1的双重靶向抗体及其用途
KR20230105972A (ko) 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
KR20220006010A (ko) 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도
TWI914375B (zh) 含有補體路徑抑制物及血管生成抑制物的融合蛋白及其用途
CN115772544A (zh) 抗vegf-a和ang-2的aav载体

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20220105

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241203

Comment text: Request for Examination of Application